Global Antibody Drug Conjugates Market Report 2019-2030

News provided by

Nov 06, 2019, 06:15 ET

DUBLIN, Nov. 6, 2019 /PRNewswire/ -- The "Antibody Drug Conjugates Market (5th Edition), 2019-2030" report has been added to ResearchAndMarkets.com's offering.

The Antibody Drug Conjugates Market (5th Edition), 2019-2030' report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.

The growing popularity and therapeutic potential of ADCs can also be correlated with an exponential increase in the number of patents that have been filed / granted; the cumulative patent count has increased from 1,395 in 2009 to over 16,500 in the first half of 2019. With more than 200 ADCs in clinical / preclinical stages of development, the industry is gradually shifting from relying on conventional technologies to newer and more robust approaches to conjugate such complex biomolecules.

Over the years, a number of well-funded start-ups / small companies, offering novel conjugation technologies, more potent warheads and advanced linker technologies, have been established. In fact, multiple licensing agreements / collaborations have been inked in the past few years between drug developers and technology providers to advance the development of pipeline ADC candidates.

Using ADCs in combination with other drug / therapy classes is an emerging concept and multiple companies are evaluating their proprietary ADC candidates in combination with other established therapeutic classes, such as immune checkpoint inhibitors, epigenetic modulators and monoclonal antibodies. In addition, several other companies have introduced certain novel types of conjugated drug molecules; example of such companies include Bicycle Therapeutics (bicycle drug conjugate), BlinkBio (tunable drug conjugates), Cellectar Biosciences (phospholipid drug conjugate), Centrose (extracellular drug conjugate), Esperance Pharmaceuticals (peptide conjugate) and Nordic Nanovector (radionucleotide conjugate).

We expect the ADC therapeutics market to grow at a healthy rate in the mid to long-term, driven by the introduction of new combination therapies involving ADCs, innovative ADC development and conjugation technologies, applications beyond oncology and the expansion of existing marketing authorizations to newer geographies across the world.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for ADCs, over the coming decade. Based on several parameters, such as target consumer segments, region-specific adoption rates and expected prices of such products, we have provided an informed estimate on the likely evolution of the market for the period 2019-2030.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. Company And Drug Profiles

6. Key Therapeutic Areas

7. Key Opinion Leaders

8. Target Competitiveness Analysis

9. Partnerships And Collaborations

10. Funding And Investment Analysis

11. Patent Analysis

12. Academic Grants

13. Key Commmercialization Strategies

14. Promotional Analysis

15. Combination Therapies

16. Novel Conjugation Technology Platforms

17. Assessment Of Non-Clinical Data, First In Human Dosing

18. Cost Price Analysis

19. Case Study: Contract Manufacturing Of Adc

20. Case Study: Companion Diagnostics For Adc Therapeutics

21. Market Forecast And Opportunity Analysis

22. SWOT ANALYSIS

23. Conclusion

24. Executive Insights

25. Appendix 1: Tabulated Data

26. Appendix 2: List Of Companies And Organizations

3SBio
5AM Ventures
Abbott
AbbVie
AbGenomics
ABL Bio
Abraxis BioScience
Abzena
ACES Pharma
Actinium Pharmaceuticals
Adagene
ADC Bio
ADC Therapeutics
Adimab
Advanced Biotechnologies Venture Fund
Advanced Proteome Therapeutics
Advantage Capital
Advent Venture Partners
Aesica Pharmaceuticals
Agensys
Agilent Technologies
Agios Pharmaceuticals
Agno Pharma
Ajinomoto Althea
Alexion Pharmaceuticals
Alger
Algeta
Alkermes
Allos Therapeutics
Allozyne
Ally Bridge Group
Almac
Alphora Research
Alta Partners
Alteogen
Amatsigroup
Ambrx
Amgen
Amgen Ventures
Amoy Diagnostics
AMPAC Fine Chemicals
AMRI
Angiex
Antikor Biopharma
APO-T
Apricot Capital
Aptuit
Aravis
Arch Pharmalabs
ArrowMark Partners
Asana BioSciences
Ash Stevens
Astellas Pharma
AstraZeneca
Asymchem Laboratories
Atlas Venture
Atreca
Auven Therapeutics
Avalon Ventures
Avanthera
Avicenna Oncology
Baxter BioPharma Solutions
Bayer HealthCare
BDC Capital
BeiGene
BerGenBio
Beth Israel Deaconess Medical Center
Bicycle Therapeutics
BioAlta
Biogen Idec
BioGeneration Ventures
BioGenex
BioMed Valley Discoveries
BioSynthesis Pharma
Biotest
Bio-Thera Solutions
BioVectra
BlinkBio
Boehringer Ingelheim
BOM Capital
Bregua Corporation
Bristol-Myers Squibb
Bryllan
BSP Pharmaceuticals
BZL Biologics
Calculus Capital
California Institute for Regenerative Medicine
Cambrex
Cambridge Innovation Capital
Cambridge Major Laboratories
Canaan
Cancer Prevention and Research Institute of Texas
Cancer Research UK
Capsugel
CARBOGEN AMCIS
Carb-X
Casdin Capital
Catalent
Cedarburg Pharmaceuticals
CEL Healthcare Fund
Celgene
Cellectar Biosciences
Cellerant Therapeutics
CellMosaic
Celltrion
Celon Laboratories
Centre for the Commercialization of Antibodies and Biologics
Centrose
Cerbios-Pharma
ChemCon
ChemSun Pharmaceutical
Children's Hospital Los Angeles
Chugai Pharmaceutical
Cisbio
Clovis Oncology
Coldstream Laboratories
Concortis Biotherapeutics
CordenPharma
Corixa
Cormorant Asset Management
Creative Biolabs
Credit Suisse First Boston Next Fund
Crescendo Biologics
Crocker Ventures
Crystal Pharma
CSPC Pharmaceutical Group
CTI Life Sciences Fund
CureMeta
Custom Pharma Services
Cytogen
CytomX Therapeutics
Daiichi Sankyo
Dalton Pharma Services
Debiopharm
Deerfield Management
DKFZ German Cancer Research Center
Dorizoe Lifesciences
DOTTIKON EXCLUSIVE SYNTHESIS
DSM Pharmaceuticals
Dyax
EirGen Pharma
Eisai
Elan Pharma
Elasmogen
Elder Pharmaceuticals
Eleven Biotherapeutics
Eli Lilly
Elusys Therapeutics
EMD Serono
Esperance Pharmaceuticals
Essex Bio-Technology
ETH Zurich
EUCODIS Bioscience
Evonik Industries
Excella
Exelixis
Farmabios
Femtogenix Ink
Ferring Pharmaceuticals
Fidelity Investments
FineTech Pharmaceutical
Fonds de solidarit FTQ
Forbius
Formex
Formosa Laboratories
Fortis Therapeutics
Fosun Pharma
Foundation Medicine
F-Prime Capital
GamaMabs Pharma
Genentech
Genmab
Gilead Sciences
Global Bio
Glycotope
Glykos
Goodwin Biotechnology
GP-Pharm
GSK
GT Biopharma
Halozyme Therapeutics
Hangzhou DAC Biotech
Harris Group
Haupt Pharma
HBM Healthcare Investments
HealthCap
Heidelberg Pharma
Helsinn Advanced Synthesis
Heraeus Deutschland
Hercules Capital
Hisun Pharmaceuticals
HOPU Investments
Human Genome Sciences
Humanwell Healthcare Group
Iconic Therapeutics
ICROM
Idifarma
IDT Australia
Igenica Biotherapeutics
Iksuda Therapeutics
ImClone Systems
ImmunoBiochem
ImmunoGen
Immunomedics
Indena
Innate Pharma
Innovate UK
Intas Pharmaceuticals
Invenra
Invivoscribe
IONTAS
iProgen Biotech
IRIX Pharmaceuticals
Janssen Biotech
Jazz Pharmaceuticals
Jennison Associates
Jiangsu Hengrui Medicine
Johnson & Johnson
Johnson Matthey (Pharma Services)
Kairos Therapeutics
Karyopharm Therapeutics
Kite Pharma
KLUS Pharma
Kyongbo Pharmaceutical
Kyowa Hakko Kirin
Labochim
LegoChem Biosciences
Leica Biosystems
Levena Biopharma
Ligand Pharmaceuticals
Light Chain Bioscience
Lilly Asia Ventures
Lilly Ventures
LinXis
Longwood Fund
Lonza
Louisiana Fund
Lumira Ventures
MAB Discovery
MabPlex
MabSpace Biosciences
MabVax Therapeutics
MacroGenics
Magenta Therapeutics
Max Delbrck Center for Molecular Medicine
MediaPharma
Medichem
MedImmune
Meditope Biosciences
Medivation
Memorial Sloan Kettering Cancer Center
Menarini
Merck
Metrics Contract Services
Millennium Pharmaceuticals
MilliporeSigma
Minakem
Minomic
Mitsubishi Tanabe Pharma
MorphoSys
Morphotek
MS Ventures
MuseChem
NanoValent Pharmaceuticals
Natco Pharma
National Cancer Institute
National Cancer Institute
NBE Therapeutics
NerPharMa
Nerviano Medical Sciences
New Enterprise Associates
Noonday Asset Management
Nordic Nanovector
Normon Laboratories
Northeast Securities Prosperity Healthcare Fund
Novartis
Novasep
Novo Holdings
Olon
Omni Chem
Oncolinx
Oncomatryx Biopharma
Onconova Therapeutics
Onyx Pharmaceuticals
OPKO Health
Orano Med
OrbiMed Advisors
Organon Teknika
Osage University Partners
OsoBio
Otsuka Pharmaceutical
Oxford BioTherapeutics
Oxford Finance
Palatin Technologies
Patheon
Paul Scherrer Institute
Penn Pharma
Perceptive Advisors
Pfanstiehl
Pfizer
Pharmaceutics International
Pharmacyclics
PharmaMar
Pharmatek
Philochem
Philogen
Pierre Fabre
Piramal Pharma Solutions
PolyTherics
Poniard Pharmaceuticals
PPF Group
PrasFarma
ProBioGen
Procos
ProJect Pharmaceutics
ProLynx
ProQuest Investments
Puma Biotechnology
QIAGEN
QS Pharma
Quantum Leap Investments
Rakuten Medical
Ramot
Recepta Biopharma
Recipharm
Redmile Group
Regeneron Pharmaceuticals
Regis Technologies
RemeGen
Research Corporation Technologies
Rho Ventures
Roche
Rock Springs Capital
Rottendorf Pharma
Royalty Pharma
Saltigo
Samsung Medical Center
Sandoz
Sanofi
Sanofi Genzyme
Sarah Cannon Research Institute
SBI Holdings
ScinoPharm
Scripps Research Institute
Seattle Genetics
Servier
Shanghai Fosun Pharmaceutical
Shanghai Fudan-zhangjiang Bio-Pharmaceutical
Shanghai Miracogen
Shanghai Pharma
Shenogen Pharma
Shire
Siamab Therapeutics
Siegfried
Silicon Valley Bank
Sinopharm Capital
Skyline Ventures
Sorrento Therapeutics
SOTIO
Spectrum Pharmaceuticals
Spirogen
SpringWorks Therapeutics
SR One
STA Pharmaceutical
Starling Ventures
Stason Pharmaceuticals
Stemcentrx
Sun Pharmaceutical Industries
Sutro Biopharma
SV Life Sciences
Swedish Orphan Biovitrum
Symphogen
Synaffix
Syndivia
Syngene
Syntagon
Syntarga
Synthon Biopharmaceuticals
Synthorx
Taiho Oncology
TaiMed Biologics
Takeda Oncology
TBD-Biodiscovery
Tekla Healthcare Investors
Tekla Life Science Investors
Teruisi Pharmaceutical
TESARO
Teva Pharmaceutical Industries
The Column Group
The Scripps Research Institute
Themelios Ventures
Theratechnologies
Thermo Fisher Scientific
Thiel Capital
ThioLogics
Third Rock Ventures
Tolmar
TopoTarget
Tot Biopharm
TPG-Axon Capital
Triphase Accelerator
Triton Funds
Tubulis Technologies
UCB
Ultragenyx Pharmaceutical
Uman Pharma
United Therapeutics
University College of London
University Medical Center Groningen
University of California
University of Freiburg
University of Georgia
University of Wisconsin Carbone Cancer Center
University of Copenhagen
UPM Pharmaceuticals
Uquifa
Vaccinex
Valeant Pharmaceuticals
VelosBio
Venrock Healthcare Capital Partners
Ventures West
Verastem Oncology
Vertex Ventures
Visterra
VivaMab
Vivo Capital
VUAB Pharma
Watson Pharmaceuticals
Wellington Management Company
Wild Ventures
Wild Family Office
WS Investments
WT Investment Advisors Fund
WuXi Biologics
WuXi PharmaTech
Xintela
Y Biologics
York University
Yuhan Corporation
Zhejiang Medicine

For more information about this report visit https://www.researchandmarkets.com/r/lquqgp

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets